SEC Filings

SEC Filings

Filing date	Description	Form	View
Aug 15, 2019	Notification that form type 10-Q will be submitted late	NT 10-Q	View HTML 0001558370-19-008211.pdf 0001558370-19-008211.rtf 0001558370-19-008211.xls
Aug 09, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000919574-19-004990.pdf 0000919574-19-004990.rtf
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000899243-19-021334.pdf 0000899243-19-021334.rtf 0000899243-19-021334.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000904454-19-000600.pdf 0000904454-19-000600.rtf 0000904454-19-000600.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0000904454-19-000602.pdf 0000904454-19-000602.rtf 0000904454-19-000602.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-005085.pdf 0001214659-19-005085.rtf 0001214659-19-005085.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-005086.pdf 0001214659-19-005086.rtf 0001214659-19-005086.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-005087.pdf 0001214659-19-005087.rtf 0001214659-19-005087.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-005088.pdf 0001214659-19-005088.rtf 0001214659-19-005088.xls
Aug 08, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-005089.pdf 0001214659-19-005089.rtf 0001214659-19-005089.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE